At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

Chardan keeps $325 price target on Alnylam, citing strong Amvuttra launch potential Most of Alnylam’s manufacturing and IP is U.S.-based, easing tariff concerns 9 Out of the Last 10 Summers this ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

Cantor Fitzgerald analyst Olivia Brayer initiated coverage with a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $250.00. The company’s shares ...

Alnylam concedes its inability to secure a judgment against Moderna’s products after the court’s claim construction. Moderna’s counterclaims and affirmative defenses were dismissed without ...

Oct 2 (Reuters) - Alnylam Pharmaceuticals (ALNY.O), opens new tab admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's (MRNA.O), opens new tab blockbuster COVID ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...

Alnylam Pharmaceuticals said Monday that a drug to treat a rare genetic heart disorder met all its goals in a late-stage clinical trial, raising the prospect that the medicine could generate ...

Alnylam Pharmaceuticals ALNY reported first-quarter 2024 adjusted loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents, primarily due to higher ...